Altimmune, Inc.

Altimmune, Inc. is a late clinical stage biopharmaceutical company focused on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. The company aims to address significant unmet medical needs in liver health through innovative drug development.

Altimmune, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ALT. The company's stock trades in US Dollars (USD), which is the currency of its home country, the United States. Investors can buy and sell ALT shares on this major US exchange during regular trading hours.

Altimmune operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on research, development, and potential commercialization of therapies for serious liver diseases. Biotechnology companies like Altimmune use biological processes and living organisms to develop drugs, often targeting complex diseases with high unmet medical needs.

Altimmune is headquartered in Gaithersburg, Maryland, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on a US exchange. Its focus on liver diseases such as MASH and alcohol-associated liver disease addresses health issues prevalent in the US and globally. While its clinical trials may involve international sites, its core business activities are centered in the United States.

Altimmune's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. This drug is being developed for multiple indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and alcohol-associated liver disease. Pemvidutide is currently in Phase 3 clinical trials, the final stage before potential regulatory approval. By targeting both GLP-1 and glucagon receptors, it aims to improve metabolic and liver health outcomes.